• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Altai Capital Management Nominates Two Highly-Qualified Candidates for Election to OraSure Board of Directors

    1/15/26 8:30:00 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care
    Get the next $OSUR alert in real time by email

    Reiterates Urgent Need for Change to Address Company's Failure to Deliver Value to Shareholders

    Altai Capital Management, L.P. ("Altai"), one of the largest shareholders and beneficial owners of approximately 5.2% of the outstanding common stock of OraSure Technologies, Inc. ("OraSure" or the "Company") (NASDAQ:OSUR), today announced that it has nominated two highly-qualified candidates, John Bertrand, Co-Founder of Digital Diagnostics, and Rishi Bajaj, President and CIO of Altai, for election to the OraSure Board of Directors (the "Board") at the 2026 Annual Meeting of Stockholders.

    The nomination follows Altai's December 17 letter to the Board outlining its serious concerns about the Company's significant share price underperformance driven by poor strategic and capital allocation decisions by management and the Board's refusal to consider alternative strategies for value creation.

    "As long-term OraSure shareholders, we remain firmly convinced in the potential of the Company despite significant underperformance, which we believe has been driven by extremely poor strategy and capital allocation decisions," said Rishi Bajaj. "It has become clear to us that the current Board is neither capable of nor willing to take the necessary steps to transform the Company, and we believe that specialized expertise and direct shareholder perspective is needed to put the Company on a better path forward to deliver substantial near- and long-term value. Both John and I would add the needed expertise and perspective that the current Board lacks, and we look forward to enthusiastically presenting our case and qualifications directly to fellow OSUR shareholders."

    Rishi Bajaj

    Mr. Bajaj founded Altai Capital Management, L.P. in 2009 and serves as its President and Chief Investment Officer. He has extensive public company board experience, and brings significant investment management, operational, and technology-sector expertise to his board roles. He currently serves on the Board of Directors of Digimarc Corporation as a member of its Audit Committee, and previously served on the boards of ContextLogic, a publicly traded business ownership platform (including as Chairman and Chief Executive Officer from 2024 to 2025), MobileIron, and ServiceSource International in various committee roles. Previously, he was a Senior Investment Analyst at Silver Point Capital and an M&A and Restructuring Analyst at Gleacher Partners. He holds a B.S. in Economics with concentrations in Finance and Statistics from The Wharton School of the University of Pennsylvania.

    John Bertrand

    Mr. Bertrand co-founded Digital Diagnostics Inc. in 2019 and has served as its Chief Executive Officer, leading the company's evolution from a research-focused organization into a global, commercial artificial intelligence platform for disease diagnosis. Previously, he spent more than 12 years in various roles at Epic Systems Corporation, including as a Business Development and Product Management Executive, where he led cross-functional teams focused on product growth, customer success, and commercialization. He has extensive board and advisory experience across healthcare and technology, currently serving as a Senior Advisor to Bain Capital since 2023, as a Senior Advisor and Executive in Residence at 8VC since 2018, and as a director of KeyCare, Surglogs, Digital Diagnostics, and Sirona Medical, with prior advisory roles at Innovaccer, iRhythm Technologies, Digital Surgery, and Matrix Capital Management. He holds a B.S. in Business Management from Purdue University and brings deep expertise in healthcare technology, artificial intelligence, and scaling innovative products to his director roles.

    About Altai Capital Management

    Altai Capital Management is a technology-focused investment firm founded in 2009 by Rishi Bajaj. Altai makes long-term investments across a diverse range of financial instruments, including debt, private equity, venture capital, and publicly traded securities. To learn more, visit www.altai.com.

    Disclaimers

    This press release and the opinions herein are for general information only, and are not intended to be, nor should they be construed as, an offer to sell or a solicitation of an offer to buy any security, a recommendation to purchase or sell any security, or legal, financial, tax, investment, or other advice.

    Altai Capital Management, L.P., Altai Capital Management, LLC, Altai Capital Osprey, LLC, Rishi Bajaj and John Bertrand (collectively, the "Participants") intend to file with the SEC a definitive proxy statement and accompanying form of proxy to be used in connection with the solicitation of proxies from the stockholders of OraSure Technologies, Inc. Stockholders are advised to read the definitive proxy statement and other documents related to the solicitation of proxies by the Participants when they become available, as they will contain important information, including additional information related to the Participants. The definitive proxy statement and an accompanying proxy card will be furnished to OraSure Technologies, Inc. stockholders and will be, along with other relevant documents, available at no charge on the SEC website at http://www.sec.gov/.

    Information about the Participants and a description of their direct or indirect interests, by security holdings or otherwise, is contained in Exhibit 1 to the Schedule 14A filed by the Participants with the SEC on January 15, 2026. This document is available free of charge from the source indicated above.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260115432907/en/

    Media Contact:



    ASC Advisors

    Taylor Ingraham / Max Rayden

    tingraham@ascadvisors.com / mrayden@ascadvisors.com

    Get the next $OSUR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OSUR

    DatePrice TargetRatingAnalyst
    1/3/2023$5.00In-line
    Evercore ISI
    2/24/2022$15.00 → $12.00Buy
    Citigroup
    9/22/2021Outperform → Market Perform
    Raymond James
    8/4/2021$11.00 → $12.50Outperform
    Raymond James
    6/28/2021$12.00 → $11.00Outperform
    Raymond James
    More analyst ratings

    $OSUR
    SEC Filings

    View All

    OraSure Technologies Inc. filed SEC Form 8-K: Other Events

    8-K - ORASURE TECHNOLOGIES INC (0001116463) (Filer)

    6/11/26 9:02:10 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure Technologies Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - ORASURE TECHNOLOGIES INC (0001116463) (Filer)

    6/3/26 4:32:44 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by OraSure Technologies Inc.

    10-Q - ORASURE TECHNOLOGIES INC (0001116463) (Filer)

    5/8/26 4:09:59 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections

    BETHLEHEM, Pa., June 11, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. ("OraSure") (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions today announced U.S. Food and Drug Administration (FDA) clearance of its Colli-Pee™•Dx Urine Collection Kit from its subsidiary DNA Genotek Inc., for use with Roche's tests for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), and Mycoplasma genitalium (MG) and run on Roche's cobas® 5800, 6800, and 8800 molecular diagnostic systems. The FDA-cleared collection kit supports at-home self-collection of first-void urine, enabling convenient sample collection at-home or in any

    6/11/26 8:00:00 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure Announces First Quarter 2026 Financial Results

    BETHLEHEM, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended March 31, 2026. "Our Q1 results were consistent with our expectations, and revenue of $27.9 million was above the midpoint of our guidance range," said Carrie Eglinton Manner, President and CEO of OTI. "We delivered gross margin expansion in Q1 and remain focused on leveraging our manufacturing capabilities and capacity to drive additional operating efficiencies." She continued, "OraSure is well positioned to accelerate our growth as we approach a ser

    5/6/26 4:05:00 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th

    BETHLEHEM, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular earnings conference call covering first quarter 2026 financial results and certain business developments for 5 p.m. ET on May 6, 2026. A webcast of the conference call will be available on the investor relations page of OraSure's website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure's website shortly after the call has ended. About OraSure Technologies, Inc. OraSure Technologies, Inc. ("OraSure" and "

    4/22/26 4:10:00 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mcmahon Robert W. was granted 46,106 shares, increasing direct ownership by 60% to 123,137 units (SEC Form 4)

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    6/5/26 4:03:11 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    Director Boyd Steven Kyle was granted 46,106 shares, increasing direct ownership by 41% to 159,568 units (SEC Form 4)

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    6/5/26 4:00:28 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    Director Marmora Lelio was granted 46,106 shares, increasing direct ownership by 45% to 148,460 units (SEC Form 4)

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    6/5/26 4:01:28 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Boyd Steven Kyle bought $224,750 worth of shares (75,000 units at $3.00), increasing direct ownership by 195% to 113,462 units (SEC Form 4)

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    5/14/26 8:55:48 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Mcgrath Kenneth J bought $66,030 worth of shares (22,021 units at $3.00), increasing direct ownership by 4% to 557,262 units (SEC Form 4)

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    3/16/26 8:01:53 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    President & CEO Eglinton Manner Carrie bought $66,033 worth of shares (22,022 units at $3.00), increasing direct ownership by 1% to 2,158,574 units (SEC Form 4)

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    3/16/26 8:01:38 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI resumed coverage on OraSure with a new price target

    Evercore ISI resumed coverage of OraSure with a rating of In-line and set a new price target of $5.00

    1/3/23 8:07:55 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    Citigroup reiterated coverage on OraSure Technologies with a new price target

    Citigroup reiterated coverage of OraSure Technologies with a rating of Buy and set a new price target of $12.00 from $15.00 previously

    2/24/22 8:34:18 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure Technologies downgraded by Raymond James

    Raymond James downgraded OraSure Technologies from Outperform to Market Perform

    9/22/21 5:02:16 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Financials

    Live finance-specific insights

    View All

    OraSure Announces First Quarter 2026 Financial Results

    BETHLEHEM, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended March 31, 2026. "Our Q1 results were consistent with our expectations, and revenue of $27.9 million was above the midpoint of our guidance range," said Carrie Eglinton Manner, President and CEO of OTI. "We delivered gross margin expansion in Q1 and remain focused on leveraging our manufacturing capabilities and capacity to drive additional operating efficiencies." She continued, "OraSure is well positioned to accelerate our growth as we approach a ser

    5/6/26 4:05:00 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th

    BETHLEHEM, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular earnings conference call covering first quarter 2026 financial results and certain business developments for 5 p.m. ET on May 6, 2026. A webcast of the conference call will be available on the investor relations page of OraSure's website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure's website shortly after the call has ended. About OraSure Technologies, Inc. OraSure Technologies, Inc. ("OraSure" and "

    4/22/26 4:10:00 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure Announces Fourth Quarter 2025 Financial Results

    BETHLEHEM, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended December 31, 2025. "Our Q4 results were consistent with our expectations, and revenue of $26.8 million was above the midpoint of our guidance range," said Carrie Eglinton Manner, President and CEO of OTI. "We supported our customers in navigating a challenging funding environment in 2025, and we are encouraged to see increasing signs of stability in key segments as we enter 2026." She continued, "We are confident that OTI is positioned to return to g

    2/25/26 4:05:00 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Leadership Updates

    Live Leadership Updates

    View All

    OraSure Technologies Appoints John D. Bertrand to its Board of Directors

    Enters into Cooperation Agreement with Altai Capital Board to Seek Shareholder Approval for Declassification at the 2026 Annual Meeting BETHLEHEM, Pa., April 16, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. ("OraSure" and "OTI") (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the appointment of John D. Bertrand to its Board of Directors as an independent director, effective immediately. Mr. Bertrand is a healthcare technology executive with more than a decade of experience driving AI-enabled innovation in diagnostics. He co-founded Digital Diagnostics Inc. and most recently served as its Chief Executive Officer,

    4/16/26 8:10:00 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance

    Calls on Company to Reach a Fair Settlement that Appoints Altai Nominees Rishi Bajaj and John Bertrand to the Board Altai Capital Management, L.P. ("Altai"), one of the largest shareholders and the beneficial owners of approximately 5% of the outstanding common stock of OraSure Technologies, Inc. ("OraSure" or the "Company") (NASDAQ:OSUR), today announced that it has delivered a letter to the OraSure Board of Directors (the "Board") outlining a five-pillar case for why change is necessary to preserve and deliver value for its investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317768148/en/ In the letter, Altai calls

    3/17/26 9:15:00 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure Technologies Appoints Steven K. Boyd to its Board of Directors

    Seasoned Investor with Deep Experience in the Healthcare and Medical Device Industries Brings Valuable Capital Markets Expertise and Investor Perspective  OraSure Board Has Added Three New Independent Directors in the Past Three Years Mara Aspinall to Step Down from the Board; Jack Kenny Appointed as Chair of the Board BETHLEHEM, Pa., Oct. 28, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. ("OTI") (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the appointment of Steven K. Boyd to its Board of Directors, as a Class II director, effective immediately. The addition of Mr. Boyd is part of OraSure's ongoing Board refr

    10/28/25 4:22:03 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by OraSure Technologies Inc.

    SC 13G/A - ORASURE TECHNOLOGIES INC (0001116463) (Subject)

    11/12/24 4:46:06 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by OraSure Technologies Inc.

    SC 13G/A - ORASURE TECHNOLOGIES INC (0001116463) (Subject)

    11/4/24 1:18:55 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by OraSure Technologies Inc.

    SC 13G - ORASURE TECHNOLOGIES INC (0001116463) (Subject)

    10/4/24 1:30:36 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care